Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report.
Vaccine
; 41(49): 7307-7312, 2023 Nov 30.
Article
en En
| MEDLINE
| ID: mdl-37949751
ABSTRACT
The WHO/MPP mRNA Technology Transfer Programme, initiated in 2021, focuses on establishing mRNA vaccine manufacturing capacity in LMICs. On 17-21 April 2023, Programme partners were convened to review technology transfer progress, discuss sustainability aspects and promote mRNA product development for diseases relevant to LMICs. To help guide product development, this report introduces key considerations for for understanding the likelihood of technical and regulatory success and of policy development and procurement for mRNA vaccines to be developed and manufactured in LMICs. The report underscores the potential for LMICs to establish sustainable mRNA R&D pipelines.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Vacunas
/
Países en Desarrollo
Idioma:
En
Año:
2023
Tipo del documento:
Article